Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review.

IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY Przegla̜d Gastroenterologiczny Pub Date : 2023-01-01 DOI:10.5114/pg.2022.116673

Gerson Domingues, Decio Chinzon, Joaquim Prado P Moraes-Filho, Juliana Tosta Senra, Marcos Perrotti, Schlioma Zaterka

{"title":"Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review.","authors":"Gerson Domingues, Decio Chinzon, Joaquim Prado P Moraes-Filho, Juliana Tosta Senra, Marcos Perrotti, Schlioma Zaterka","doi":"10.5114/pg.2022.116673","DOIUrl":null,"url":null,"abstract":"Introduction: A new therapeutic class, potassium-competitive acid blockers (P-CABs), has emerged in Brazil to promote a superior antisecretory effect addressing the unmet needs related to acid-related disease management. Vonoprazan fumarate showed a good safety profile and was approved by the Brazilian regulatory agency - ANVISA.Aim: This narrative review was conducted to review the general concepts regarding P-CABs, focussing on vonoprazan fumarate.Material and methods: A literature search was conducted through April-May 2021 using official databases with a combination of MeSH controlled vocabulary and text words. The authors selected articles that described pivotal and novel insights about P-CABs and vonoprazan fumarate.Results: Vonoprazan is a drug of the P-CABs class newly approved for the management of acid-related diseases in Brazil. P-CABs achieve rapid, potent, and prolonged acid suppression (including night-time) and promise to address some unmet clinical needs in GERD. Furthermore, considering the difficulties encountered in attaining effective symptomatic control - particularly at night - using currently available PPIs, this new drug class is promising.Conclusions: This review brings important information about vonoprazan, a new therapeutic option in Brazil, which may be considered as a valuable tool for managing acid-related diseases.","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"18 1","pages":"47-55"},"PeriodicalIF":1.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/24/ac/PG-18-47138.PMC10050988.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Przegla̜d Gastroenterologiczny","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pg.2022.116673","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: A new therapeutic class, potassium-competitive acid blockers (P-CABs), has emerged in Brazil to promote a superior antisecretory effect addressing the unmet needs related to acid-related disease management. Vonoprazan fumarate showed a good safety profile and was approved by the Brazilian regulatory agency - ANVISA.

Aim: This narrative review was conducted to review the general concepts regarding P-CABs, focussing on vonoprazan fumarate.

Material and methods: A literature search was conducted through April-May 2021 using official databases with a combination of MeSH controlled vocabulary and text words. The authors selected articles that described pivotal and novel insights about P-CABs and vonoprazan fumarate.

Results: Vonoprazan is a drug of the P-CABs class newly approved for the management of acid-related diseases in Brazil. P-CABs achieve rapid, potent, and prolonged acid suppression (including night-time) and promise to address some unmet clinical needs in GERD. Furthermore, considering the difficulties encountered in attaining effective symptomatic control - particularly at night - using currently available PPIs, this new drug class is promising.

Conclusions: This review brings important information about vonoprazan, a new therapeutic option in Brazil, which may be considered as a valuable tool for managing acid-related diseases.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

钾竞争性酸阻滞剂——一类新的治疗药物，及其在酸相关疾病中的作用:述评

一种新的治疗类别，钾竞争性酸阻滞剂(p - cab)，已经在巴西出现，以促进卓越的抗分泌作用，解决与酸相关疾病管理相关的未满足的需求。富马酸伏诺哌嗪显示出良好的安全性，并获得巴西监管机构ANVISA的批准。目的:本综述综述了p - cab的一般概念，重点是富马酸伏诺哌赞。材料和方法:在2021年4月至5月期间，使用MeSH控制词汇和文本词相结合的官方数据库进行文献检索。作者选择了描述关于p - cab和富马酸伏诺哌嗪的关键和新颖见解的文章。结果:Vonoprazan是巴西新近批准用于治疗酸相关疾病的p - cab类药物。p - cab实现快速、有效和持久的抑酸(包括夜间)，并有望解决一些未满足的胃食管反流临床需求。此外，考虑到使用目前可用的质子泵抑制剂获得有效的症状控制所遇到的困难，特别是在夜间，这种新型药物很有希望。结论:本综述提供了vonoprazan的重要信息，这是巴西的一种新的治疗选择，可能被认为是治疗酸相关疾病的有价值的工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Przegla̜d Gastroenterologiczny GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

2.20

自引率

7.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Gastroenterology Review is a journal published each 2 months, aimed at gastroenterologists and general practitioners. Published under the patronage of Consultant in Gastroenterology and Polish Pancreatic Club.